Audit: QRS - Ketoglutaric Acid for Hair Regrowth
Audit conducted on 11/10/2026 12:33 using AI4L / Opus 5.5
Summary
| Items | Count |
|---|---|
| Total | 94 |
| Passed | 87 |
| Failed | 0 |
| N/A | 7 |
| Pass Rate | 100.00% |
- Total = Passed + Failed + N/A
- Pass Rate = Passed / (Passed + Failed) × 100
- N/A items are excluded from the pass rate calculation
1. General Rules
| # | Description | Result | Comments |
|---|---|---|---|
| 1.1 | Every claim, magnitude, label, recommendation, and statement in the QRS is literally supported by content in the source ER. | 🟢 | Lede, protocol, time cells, tiers, gates, markers and cadence all trace to ER sections (Conclusion, Therapeutic Protocol, Practical Considerations, Monitoring, Key Interactions) |
| 1.2 | Where the ER uses cautious phrasing (“not formally studied”, “None documented in human trials to date”, “theoretical concern”, “data are limited”), the QRS uses the same phrasing. | 🟢 | “(theoretical)”, “(no safety data)”, “no hair-specific human protocol exists”, “animal data only” carried over |
| 1.3 | The QRS never strengthens an ER claim (e.g., “not formally studied” → “not required”) or softens one (e.g., “do not use during pregnancy” → “use with caution during pregnancy”). | 🟢 | Interaction severities (monitor/caution) and contraindication conditions match ER |
| 1.4 | The QRS does not relabel an ER fact under a different decision category. A “Benefit-Modifying Factor” from ER section is not surfaced as a “Caution”; a “Risk-Modifying Factor” is not surfaced as a “Side Effect”; etc. | 🟢 | |
| 1.5 | PubMed IDs, study citations, expert names, clinical trial identifiers (NCT*), and brand names appear in the QRS only if they appear in the source ER for the same fact. | 🟢 | Only brand Stemoxydine, present in ER for the same fact; no PMIDs or NCT IDs |
| 1.6 | The QRS does not introduce new attributions. | 🟢 |
2. Focus, Tone & Audience
| # | Description | Result | Comments |
|---|---|---|---|
| 2.1 | The QRS follows the tone of the ER, which is determined by the ER’s own language, phrasing, and framing. | 🟢 | |
| 2.2 | The tone of the QRS is simultaneously expert, accessible, objective, and data-driven, but also empowering and encouraging | 🟢 | |
| 2.3 | The QRS reads as a trusted, knowledgeable guide rather than a prescriptive doctor | 🟢 | |
| 2.4 | The QRS avoids language that implies medical or clinical advice | 🟢 | |
| 2.5 | The QRS “presents information” instead of “providing guidance”, “recommending”, or “advising” | 🟢 | |
| 2.6 | The QRS never addresses “the reader” directly — it presents evidence, not guidance | 🟢 | |
| 2.7 | The QRS is written in plain language, avoiding unnecessary medical jargon | 🟢 | Technical terms expanded (AKG, eGFR, NSAIDs, OAT1); ‘telogen/anagen’ rendered as resting follicles entering growth |
| 2.8 | Information is presented in a concise and very compact manner | 🟢 | |
| 2.9 | It DOES NOT address the reader directly | 🟢 | |
| 2.10 | The target audience is health- and longevity-oriented adults who are risk-aware, proactive, and actively seeking to optimize health or apply the intervention under review. | 🟢 | |
| 2.11 | The target audience is willing to employ lifestyle and behavioral changes as well as follow protocols that may be inconvenient, costly, or require effort. | 🟢 | |
| 2.12 | The document is NOT written for the general population, who are unwilling to employ lifestyle and behavioral changes or follow protocols that may be inconvenient, costly, or require effort. | 🟢 | |
| 2.13 | Framing, takeaways, and risk/benefit weighting throughout the document reflect this audience, including where an intervention’s signal for the average person differs from its signal for this audience. | 🟢 | |
| 2.14 | The document’s own voice frames usage in longevity terms, not “anti-aging” (e.g., “anti-aging clinics”, “anti-aging community”, “anti-aging medicine”). Proper names that contain “anti-aging” (e.g., “American Academy of Anti-Aging Medicine”) are quoted verbatim. | 🟢 | “longevity supplement”, “Longevity-style oral protocol”; no ‘anti-aging’ |
| 2.15 | The document’s own voice uses formal clinical and scientific terminology, not colloquial or consumer-grade language (e.g., “oral medication” not “pill(s)”; “oral” / “administered orally” not “taken by mouth” / “given by mouth”; “injection” not “shot”; “adverse event” not “bad reaction”). This holds on EVERY surface, including the QRS lede — the stricter plain-language bar (see 2.7) does not license lay phrasing for route of administration. Direct quotes from sources are exempt. | 🟢 | “oral” used throughout; no lay route phrasing |
3. Template Integrity
| # | Description | Result | Comments |
|---|---|---|---|
| 3.1 | The following labels and headings on the QRS are fixed and not modified: Card and section headings: “Protocol”, “Time to effect”, “Benefits”, “Risk & Side Effects”, “Monitoring”, “Qualitative Assessment”; Gate headings: “Contraindications”, “Key Interactions”; Tier labels: “High”, “Medium”, “Low”, “Speculative”; Table column headers in Monitoring: “Marker”, “Target”, “Why” | 🟢 | |
| 3.2 | All “…” from the [qrs_template] are present in the the QRS. | 🟢 | All template spans present; marker_# expanded to 1-4, qualitative_item_# to 1-5 |
| 3.3 | Spans that are not addressed in a checklist item are left unchanged | 🟢 | website spans, footer and comments unchanged |
4. Formatting
| # | Description | Result | Comments |
|---|---|---|---|
| 4.1 | When the source ER section is empty, the QRS uses the ER’s own empty-state phrasing verbatim. Typical phrasings are “None documented in human trials to date” and “Not formally studied” | 🟢 | Empty High/Medium tiers handled via display:none per 12.5/13.5; no other empty ER section |
| 4.2 | Where the ER presents a bulleted item as “Label: content”, the QRS uses the ER’s bold label verbatim as the cell or row label. | 🟢 | Protocol labels and interaction labels match ER bold labels |
| 4.3 | Labels are not paraphrased, abbreviated, or invented. | 🟢 | |
| 4.4 | The QRS DOES NOT use emoji indicators (no 🟩, 🟥, 🟨, etc.). Color and emphasis are conveyed through CSS and bold labels. | 🟢 | |
| 4.5 | The QRS is designed to render on one A4 page. Any section that has more content in the ER than fits the per-section budget is condensed by the LLM, not extended onto a second page. | 🟢 | ER sections condensed (protocol 11 bullets to 3 cells, interactions trimmed of mechanisms and no-interaction items) |
5. Metadata
| # | Description | Result | Comments |
|---|---|---|---|
| 5.1 | The metadata is placed inside a single HTML comment that is the first element after “<!doctype html>” and before any other comment, head, or body content. | 🟢 | |
| 5.2 | Inside that HTML comment the YAML block is delimited by a line “—” opening and a line “—” closing. Text before the opening “—” is permitted but is not parsed as YAML. | 🟢 | |
| 5.3 | The metadata is not visible in any rendered view of the QRS and is not surfaced by any other element on the sheet. | 🟢 | |
| 5.4 | All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting. | 🟢 | duration quoted because value contains a colon |
| 5.5 | The filename of the source ER is stated as “er_filename: [er_filename]” | 🟢 | |
| 5.6 | Version of the QRS.md file used to create the document is stated as “qrs_prompt_version: [Version of QRS.md]” | 🟢 | 26.10.8 matches QRS.md |
| 5.7 | Creation date and time of the document is stated as “qrs_creation_date: [YYYY-MMDD-HHMM]” (e.g., 2026-0501-1430) | 🟢 | 2026-1011-1201 |
| 5.8 | The nickname of the AI used to create the document is stated as “qrs_creator_ai_nickname: [qrs_creator_ai_nickname]” | 🟢 | |
| 5.9 | The nickname of the AI is just a single word model name without version, etc. (e.g., Opus, Sonnet, Grok, Gemini, ChatGPT) | 🟢 | |
| 5.10 | The full name of the AI used to create the document is stated as “qrs_creator_ai_fullname: [qrs_creator_ai_fullname]” | 🟢 | |
| 5.11 | The full name of the AI consists of the [qrs_creator_ai_nickname] and the model version number and no additional qualifier (e.g., Opus 4.6, Sonnet 3.2, Grok 4.5, Gemini 3.1, ChatGPT 5.4) | 🟢 | |
| 5.12 | The filename of the document is stated as “qrs_filename: [filename of this document]” | 🟢 | |
| 5.13 | All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting. | 🟢 |
6. Page Title & Header
| # | Description | Result | Comments |
|---|---|---|---|
| 6.1 | [page_title] is set to the [canonical_topic] of the ER frontmatter followed by “ - Quick Reference Sheet” (e.g., “Intervention - Quick Reference Sheet”). The [canonical_topic] is HTML-entity-encoded as needed (e.g., & for &) |
🟢 | |
| 6.2 | [header_topic] is set to the [canonical_topic] of the ER frontmatter, with HTML entities encoded as needed (e.g., & for &) |
🟢 | |
| 6.3 | [header_subline_date] is set to [qrs_creation_date reformatted as MM/DD/YYYY] | 🟢 | 10/11/2026 |
| 6.4 | [header_subline_model] is set to [qrs_creator_ai_fullname] | 🟢 | |
| 6.5 | No additional header content appears: no badge, version stamp, AKA / alternate names line, source-AI attribution, audit date, or QRS variant marker. | 🟢 |
7. At-A-Glance Section
| # | Description | Result | Comments |
|---|---|---|---|
| 7.1 | [at_a_glance] opens by saying what the intervention is — its kind (e.g., dietary supplement, prescription medication, peptide, plant, procedure, practice) — and what it is used for, in plain language, before any verdict on the evidence | 🟢 | Opens with “a natural energy-pathway compound sold as a longevity supplement, draws interest for thinning hair” |
| 7.2 | [at_a_glance] is dense, execution-oriented summary of the ER Conclusion section |
🟢 | |
| 7.3 | [at_a_glance] is no longer than 70 words | 🟢 | 70 words (wc -w) |
| 7.4 | Every fact in [at_a_glance] is supported by a distinct passage in the ER. | 🟢 | |
| 7.5 | It DOES NOT use acronyms or technical classifications that require specialist knowledge, uses plain-language terms instead | 🟢 | |
| 7.6 | It DOES NOT cite specific trials (names, years, sample sizes, p-values) | 🟢 | |
| 7.7 | It DOES NOT cite effect sizes, relative risks, or statistical results | 🟢 |
8. Contraindications
| # | Description | Result | Comments |
|---|---|---|---|
| 8.1 | The section is derived from the ER Key Interactions & Contraindications section |
🟢 | |
| 8.2 | [stop_items] represent the Contraindications from the ER | 🟢 | All five ER ‘Populations who should avoid’ entries present |
| 8.3 | Individual [stop_items] are formatted as <li></li> | 🟢 | |
| 8.4 | Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact. | 🟢 | |
| 8.5 | Parenthetical qualifiers from the ER bullet — time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely). | 🟢 | 10.3 mg/dL and eGFR below 30 thresholds and calcium-AKG condition preserved |
| 8.6 | When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol. | N/A | ER uses no ranking notation in contraindications |
| 8.7 | The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no population, condition, or scenario for which the intervention should be avoided, deferred, or used only under specialist supervision. |
🟢 | Section populated; ER names populations to avoid |
| 8.8 | If the section is left empty, an HTML comment inside the [stop_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g. | N/A | Section is not empty |
9. Key Interactions
| # | Description | Result | Comments |
|---|---|---|---|
| 9.1 | The section is derived from the ER Key Interactions & Contraindications section |
🟢 | |
| 9.2 | [caution_items] represent the Key Interactions from the ER, excluding any that are already listed as Contraindications | 🟢 | 11 ER interactions included; the two ‘no interaction expected/known’ items omitted |
| 9.3 | Individual [caution_items] are formatted as <li></li> | 🟢 | |
| 9.4 | Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact. | 🟢 | |
| 9.5 | Parenthetical qualifiers from the ER bullet — example drug lists, time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely). | 🟢 | Example drug lists and calcium-AKG qualifiers preserved; Stemoxydine parenthetical trimmed, not dropped |
| 9.6 | When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol. | N/A | ER uses no ranking notation in interactions |
| 9.7 | The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no interaction, additive effect, or exposure that changes how the intervention is used. |
🟢 | Section populated |
| 9.8 | If the section is left empty, an HTML comment inside the [caution_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g. | N/A | Section is not empty |
10. Protocol
| # | Description | Result | Comments |
|---|---|---|---|
| 10.1 | The section is derived from the ER Protocol section |
🟢 | |
| 10.2 | The three sets of [action] items cover the three most important actionable implementation aspects from the ER Protocol section |
🟢 | |
| 10.3 | If less that three distinct actionable implementation aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing. | N/A | ER provides three actionable aspects |
| 10.4 | All used [action_#label], [action#value], [action#_sub] items are filled with meaningful content derived from the ER Protocol section. |
🟢 |
11. Time to Effect
| # | Description | Result | Comments |
|---|---|---|---|
| 11.1 | The three sets of [time] items cover the three most important time-to-effect aspects from the ER | 🟢 | |
| 11.2 | The sets are picked and ordered by the magnitude of the related benefit | 🟢 | |
| 11.3 | If less that three distinct time-to-effect aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing. | N/A | Three time-to-effect aspects available in ER |
| 11.4 | All used [time_#label], [time#value], [time#_sub] items are filled with meaningful content derived from the ER. | 🟢 | |
| 11.5 | If the ER does not provide any information on time to effect, the section is removed completely from the Protocol Panel |
N/A | ER provides time-to-effect information |
12. Benefits
| # | Description | Result | Comments |
|---|---|---|---|
| 12.1 | The section is derived from the ER Expected Benefits section |
🟢 | |
| 12.2 | Key variables are [benefits_high], [benefits_medium], [benefits_low], [benefits_speculative] | 🟢 | |
| 12.3 | Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact. | 🟢 | |
| 12.4 | Parenthetical content — including effect sizes, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved. | 🟢 | |
| 12.5 | If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing. | 🟢 | benefits_high and benefits_medium set to display: none |
13. Risks
| # | Description | Result | Comments |
|---|---|---|---|
| 13.1 | The section is derived from the ER Potential Risks & Side Effects section |
🟢 | |
| 13.2 | Key variables are [risks_high], [risks_medium], [risks_low], [risks_speculative] | 🟢 | |
| 13.3 | Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact. | 🟢 | |
| 13.4 | Parenthetical content — including frequencies, severity grades, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved. | 🟢 | |
| 13.5 | If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing. | 🟢 | risks_high and risks_medium set to display: none |
14. Monitoring
| # | Description | Result | Comments |
|---|---|---|---|
| 14.1 | The section is derived from the ER Monitoring section |
🟢 | |
| 14.2 | All measurable/quantifiable biomarkers from the Monitoring section are listed |
🟢 | All four ER table biomarkers listed |
| 14.3 | [monitoring_cadence] is populated with the monitoring cadence/frequency derived from the ER Monitoring section. It is not left with placeholder text or empty. |
🟢 |
15. Qualitative Assessment
| # | Description | Result | Comments |
|---|---|---|---|
| 15.1 | The section is derived from the ER Monitoring section |
🟢 | |
| 15.2 | All subjective/qualitative biomarkers from the Monitoring section are listed |
🟢 | All five ER qualitative markers listed verbatim |
Issues 11/10/2026 12:33
Pass rate 100.00%. No issues found.
Issues 11/10/2026 12:28
- 4.2 / 4.3 — Interaction labels not verbatim: The Key Interactions items at QRS lines 555 and 564 insert invented glosses (“hair actives blocking enzymes that AKG fuels:”, “acting on cellular self-recycling:”) into the ER bold labels “Cosmetic prolyl hydroxylase inhibitors (diethyl pyridine-2,4-dicarboxylate, marketed as Stemoxydine)” and “Other autophagy-targeting agents (rapamycin, metformin, spermidine)”.
- 9.4 — Mechanistic rationale in item: The Stemoxydine caution item (QRS line 555) carries the mechanistic explanation “blocking enzymes that AKG fuels”, which the item rule excludes.
Fixes 11/10/2026 12:28
- 4.2 / 4.3 — Interaction labels restored verbatim: Removed the invented glosses so the items read “Cosmetic prolyl hydroxylase inhibitors (marketed as Stemoxydine)” (trimmed ER parenthetical) and “Other autophagy-targeting agents (rapamycin, metformin, spermidine)” (ER label verbatim).
- 9.4 — Mechanistic rationale removed: Dropped “hair actives blocking enzymes that AKG fuels” from the Stemoxydine caution item, leaving only the key fact and the “monitor (theoretical)” rating.
Issues 11/10/2026 12:24
- 2.7 — Unexplained specialist jargon remains: “Cosmetic prolyl hydroxylase inhibitors” (line 555), “Other autophagy-targeting agents” (line 564) and “phototrichogram or trichoscopy count” (line 638) are left without plain-language glosses, while other technical terms on the sheet are explained.
Fixes 11/10/2026 12:24
- 2.7 — Glossed remaining specialist jargon: Added ER-derived plain-language glosses: “Cosmetic prolyl hydroxylase inhibitors (hair actives blocking enzymes that AKG fuels: Stemoxydine)”, “Other autophagy-targeting agents (acting on cellular self-recycling: …)”, and replaced “phototrichogram or trichoscopy count” with “hairs counted per area on magnified photographs or scalp imaging”.
Issues 11/10/2026 12:22
- 2.7 — NSAIDs acronym left unexplained: The Key Interactions item at QRS line 561 reads “Over-the-counter NSAIDs (ibuprofen, naproxen)”, dropping the ER’s expansion “non-steroidal anti-inflammatory drugs” (ER line 286) and leaving the acronym unexplained for lay readers.
Fixes 11/10/2026 12:22
- 2.7 — NSAIDs acronym expanded: Changed the Key Interactions item from “Over-the-counter NSAIDs (ibuprofen, naproxen)” to the ER’s label “Over-the-counter NSAIDs (non-steroidal anti-inflammatory drugs: ibuprofen, naproxen)”.
Issues 11/10/2026 12:18
- 2.7 — Unexplained jargon in interactions: “Thiazide diuretics” (line 557) and “Organic anion transporter 1 substrates” (line 560) drop the plain-language glosses given in the ER (“urine-increasing blood-pressure drugs”; “a kidney protein that clears drugs into urine”), leaving specialist terms unexplained.
Fixes 11/10/2026 12:18
- 2.7 — Restored plain-language interaction glosses: Added the ER’s glosses to “Thiazide diuretics (urine-increasing blood-pressure drugs: …)” and “Organic anion transporter 1 (a kidney protein that clears drugs into urine) substrates (…)” in Key Interactions.
Issues 11/10/2026 12:16
- 4.5 — Sheet not condensed to A4: The Key Interactions gate (lines 553-565) lists 11 items with full explanatory parentheticals (e.g., “Organic anion transporter 1 (a kidney protein that clears drugs) substrates”, “Over-the-counter NSAIDs (non-steroidal anti-inflammatory drugs: ibuprofen, naproxen)”), which together with the rest of the sheet overflows a single A4 page.
Fixes 11/10/2026 12:16
- 4.5 — Key Interactions condensed: Trimmed explanatory parentheticals in three Key Interactions items (Stemoxydine “a cosmetic hair active”, organic anion transporter 1 “a kidney protein that clears drugs”, NSAIDs expansion) while keeping all named example drugs, to tighten the sheet toward one A4 page.
Issues 11/10/2026 12:13
- 2.7 — Unexplained clinical jargon in gates: Line 546 “Active alopecia areata” gives no plain-language meaning (the Risks card says “autoimmune patchy hair loss”), and line 561 “Over-the-counter NSAIDs” leaves the acronym unexpanded although the ER expands it.
Fixes 11/10/2026 12:13
- 2.7 — Unexplained clinical jargon in gates: Changed “Active alopecia areata (theoretical, based on genetic association)” to add “autoimmune patchy hair loss” as a plain-language gloss, and expanded “NSAIDs” to “non-steroidal anti-inflammatory drugs” as in the ER.
Issues 11/10/2026 12:08
- 2.2 / 2.13 — Takeaway drops audience framing: The at-a-glance (line 433) ends with “Its hair benefit in people is unknown.”, omitting the ER Conclusion’s framing of AKG as “an early, low-cost experiment” for adults “willing to experiment carefully”, leaving a purely negative takeaway.
- 2.7 — Unexplained jargon in interactions: “Cosmetic prolyl hydroxylase inhibitors (Stemoxydine)” (line 555) and “Organic anion transporter 1 substrates” (line 560) appear without the plain-language explanations the ER provides.
- 13.4 — Parenthetical kept in risk: risks_low (line 583) retains the parenthetical “(alopecia areata)” in “possible link to autoimmune patchy hair loss (alopecia areata)”.
Fixes 11/10/2026 12:08
- 2.2 / 2.13 — Restored experiment framing: Rewrote the closing at-a-glance sentence to the ER Conclusion’s “It remains an early, low-cost experiment; hair benefit in people is unknown.” and tightened earlier wording to stay at 70 words.
- 2.7 — Plain-language interaction labels: Added “a cosmetic hair active” to the Stemoxydine item and the ER’s “(a kidney protein that clears drugs)” explanation to the Organic anion transporter 1 item.
- 13.4 — Removed risk parenthetical: Changed “possible link to autoimmune patchy hair loss (alopecia areata)” to “possible link to autoimmune patchy hair loss” in risks_low.
Issues 11/10/2026 12:06
- 2.7 — Acronyms AKG and eGFR unexpanded: “AKG” is used from action_1_sub (line 450) onward and “eGFR” in the kidney-disease contraindication (line 545) without ever being expanded, although the ER defines both.
- 4.2 / 4.3 — Vitamin C label altered: The interaction at line 563 is labelled “Vitamin C, high doses” instead of the ER’s bold label “Vitamin C” verbatim.
Fixes 11/10/2026 12:06
- 2.7 — Expanded AKG and eGFR: Added “(alpha-ketoglutarate)” after the first “calcium AKG” in action_1_sub and changed “eGFR below 30” to “eGFR, estimated kidney function, below 30” in the kidney-disease contraindication.
- 4.2 / 4.3 — Restored Vitamin C label: Changed the interaction label “Vitamin C, high doses” back to the ER’s verbatim bold label “Vitamin C”.
Issues 11/10/2026 12:04
- 2.7 — Specialist jargon in benefits: The Speculative benefits line (QRS line 531) uses “Telogen-to-anagen activation” and “dermal papilla protection” where plain terms (resting follicles entering growth; protection of follicle signaling cells) are available from the ER.
Fixes 11/10/2026 12:04
- 2.7 — Plain terms in benefits: Replaced “Telogen-to-anagen activation with topical use” with “Resting follicles entering growth with topical use” and “dermal papilla protection” with “protection of follicle signaling cells” in the Speculative benefits line.